Skip to main content
. 2023 Nov 13;19:913–928. doi: 10.2147/TCRM.S434235

Table 2.

Disease Characteristics of the Study Subjects

Comorbidity Variable Category N (%) Number of DRPs P-value*
Mean (SD)
Hypertension Without 65 (13.24) 2.66 (1.68) 0.005
With 426 (86.76) 3.41 (1.81)
Dyslipidemia Without 169 (34.42) 3.20 (1.90) 0.329
With 322 (65.58) 3.37 (1.77)
Myocardium infarction Without 407 (82.89) 3.19 (1.83) <0.001
With 84 (17.11) 3.88 (1.59)
Heart failure Without 452 (92.06) 3.21 (1.78) <0.001
With 39 (7.94) 4.46 (1.83)
Stroke Without 475 (96.74) 3.29 (1.81) 0.313
With 16 (3.26) 3.87 (1.86)
Chronic obstructive pulmonary disease Without 478 (97.35) 3.31 (1.82) 0.854
With 13 (2.65) 3.31 (1.70)
Peptic ulcer disease Without 486 (98.98) 3.31 (1.82) 0.895
With 5 (1.02) 3.20 (1.09)
Liver disease Without 484 (98.57) 3.35 (0.08) 0.100
With 7 (1.43) 4.43 (0.84)
Chronic kidney disease Without 457 (93.08) 3.27 (1.78) 0.205
With 34 (6.92) 3.82 (2.15)
Thyroid dysfunction Without 441 (89.82) 3.34 (1.83) 0.401
With 50 (10.18) 3.06 (1.60)
Asthma Without 460 (93.69) 3.31 (1.83) 0.803
With 31 (6.31) 3.35 (1.62)
Mean (SD) Correlation coefficient
Charlson comorbidity index 3.85 (0.93) 0.130 0.004
Estimated 10-year survival (%) 0.55 (0.24) −0.130 0.004

Note: *Statistical significance was set at a 2-sided P<0.05.

Abbreviation: DRPs, drug-related problems.